Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds
Open Access
- 14 October 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 22, 994-1003
- https://doi.org/10.1016/j.omtn.2020.10.013
Abstract
No abstract availableFunding Information
- Novo Nordisk Fonden
- Danmarks Grundforskningsfond
This publication has 29 references indexed in Scilit:
- Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell lineInvestigational New Drugs, 2012
- A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancerEJNMMI Research, 2012
- Rational Truncation of an RNA Aptamer to Prostate-Specific Membrane Antigen Using Computational Structural ModelingNucleic Acid Therapeutics, 2011
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumorsNature Biotechnology, 2009
- Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in miceJCI Insight, 2008
- TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human CancerAdvances in Cancer Research, 2008
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimerasNature Biotechnology, 2006
- Aptamer mediated siRNA deliveryNucleic Acids Research, 2006
- Nanoparticle-Aptamer BioconjugatesCancer Research, 2004
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990